ConvaTec logo

CTEC - ConvaTec News Story

236.9p -20.8  -8.1%

Last Trade - 30/07/21

Large Cap
Market Cap £5.19bn
Enterprise Value £5.89bn
Revenue £1.36bn
Position in Universe 181st / 1800

ConvaTec Group PLC - Total Voting Rights

Tue 1st June, 2021 11:45am
RNS Number : 4333A
ConvaTec Group PLC
01 June 2021

ConvaTec Group Plc ("the Company") - Total Voting Rights

Reading, United Kingdom (1 June 2021)

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 May 2021, the Company's issued capital with voting rights consisted of 2,013,822,670 ordinary shares of 10p each ('Shares'). The Company does not hold any Shares in Treasury at the date of this disclosure.

The above figure (2,013,822,670) can be used by shareholders as the denominator for the calculations by which to determine if they are required to notify their interest in, or a change to, their interest in the Company under the UK Financial Conduct Authority's Disclosure and Transparency Rules. 



Analysts and Investors

Kate Postans, Vice President, Investor Relations                                                +44 (0)7826 447 807



Buchanan: Charles Ryland/Chris Lane/ Hannah Ratcliff                                     +44 (0)207 466 5000  



ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92


About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our vision, which encompasses our purpose, is: Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.